297 related articles for article (PubMed ID: 37559996)
21. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
22. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
23. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
25. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
27. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. Safety of combining radiotherapy with immune-checkpoint inhibition.
Hwang WL; Pike LRG; Royce TJ; Mahal BA; Loeffler JS
Nat Rev Clin Oncol; 2018 Aug; 15(8):477-494. PubMed ID: 29872177
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence.
Okobi TJ; Uhomoibhi TO; Akahara DE; Odoma VA; Sanusi IA; Okobi OE; Umana I; Okobi E; Okonkwo CC; Harry NM
Cureus; 2023 Jun; 15(6):e40031. PubMed ID: 37425564
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Qian FF; Han BH
Chin Med J (Engl); 2020 Oct; 133(20):2444-2455. PubMed ID: 32969861
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.
Yang Y; Tan L; Hu J; Li Y; Mao Y; Tian Z; Zhang B; Ma J; Li H; Chen C; Chen K; Han Y; Chen L; Liu J; Yu B; Yu Z; Li Z;
Dis Esophagus; 2022 Nov; 35(11):. PubMed ID: 35649396
[TBL] [Abstract][Full Text] [Related]
37. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Memon H; Patel BM
Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
[TBL] [Abstract][Full Text] [Related]
39. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
Jindal V; Gupta S
Mol Neurobiol; 2018 Aug; 55(8):7072-7078. PubMed ID: 29383686
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]